Akari Therapeutics

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of Nomacopan (Coversin) to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Akari Therapeutics

We develop life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways.

Please be advised that our lead product candidate, Coversin, was recently renamed nomacopan following its acceptance as an International Nonproprietary Name by the World Health Organization.

RECENT PRESS RELEASES

Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019

Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering

Change of AGM Venue on June 27, 2019

Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)

Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress

LONDON

NEW YORK

EXPANDED ACCESS POLICY

Main Content